CD4 and neoplasm: Our group recently evaluated the effect of EZH2 inhibition on bladder tumors using a fully immunocompetent, carcinogen-induced mouse model of muscle-invasive bladder cancer, finding that targeting EZH2 not only inhibited tumor progression but also induced immune responses including upregulated MHC II, increased CD3+ tumor-infiltrating lymphocytes (NK, CD4+, CD8+), and tertiary lymphoid structures (23).